Screener Summaries Updates Institutions Sign In More Updates › Other Events › IVVD Other Events · Jul 6, 2026
Invivyd, Inc. announced it received a twelve-month advanced notice regarding the termination of the Emergency Use… IVVD Invivyd, Inc.
Invivyd, Inc. announced it received a twelve-month advanced notice regarding the termination of the Emergency Use Authorization (EUA) for its product PEMGARDA®. The company is currently coordinating next steps with the U.S. Food and Drug Administration (FDA) following this notification. Invivyd, Inc. is a biotechnology company focused on developing therapies for infectious diseases.
More from Invivyd, Inc. Invivyd reports positive Phase 3 LIBERTY topline results for VYD2311, plans BLA submission via Accelerated Approval Program Sep 29, 2026 Invivyd appointed Marc Elia, its Chairman of the Board, as Chief Executive Officer effective August 30, 2026 Sep 1, 2026 Invivyd reported second quarter 2026 financial results with PEMGARDA net product revenue of $14.3 million, a 21%… Aug 13, 2026 Invivyd, Inc. received a deficiency letter from Nasdaq on July 23, 2026, notifying the company that its common stock… Jul 24, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
